US Patent

US9486426 — Method of administration of gamma hydroxybutyrate with monocarboxylate transporters

Method of Use · Assigned to Jazz Pharmaceuticals Ireland Ltd · Expires 2033-03-15 · 7y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of administering gamma hydroxybutyrate (GHB) to a patient by avoiding certain medications that affect its efficacy.

USPTO Abstract

One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1532 — sodium-oxybate
U-1532 —

Patent Metadata

Patent number
US9486426
Jurisdiction
US
Classification
Method of Use
Expires
2033-03-15
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.